Endocyte Company Profile (NASDAQ:ECYT)

About Endocyte

Endocyte logoEndocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: ECYT
  • CUSIP: 29269A10
Key Metrics:
  • Previous Close: $3.13
  • 50 Day Moving Average: $3.07
  • 200 Day Moving Average: $3.39
  • 52-Week Range: $2.65 - $5.63
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.46
  • P/E Growth: 0.00
  • Market Cap: $132.28M
  • Outstanding Shares: 42,263,000
  • Beta: 1.27
Profitability:
  • Net Margins: -58,957.14%
  • Return on Equity: -24.71%
  • Return on Assets: -23.86%
Debt:
  • Current Ratio: 34.32%
  • Quick Ratio: 34.32%
Additional Links:
Companies Related to Endocyte:

Analyst Ratings

Consensus Ratings for Endocyte (NASDAQ:ECYT) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.67 (208.84% upside)

Analysts' Ratings History for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetDetails
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details
5/4/2016Cowen and CompanyReiterated RatingBuyView Rating Details
5/4/2016WedbushReiterated RatingOutperform$8.00View Rating Details
11/4/2015Royal Bank Of CanadaLower Price TargetOutperform$13.00 -> $10.00View Rating Details
9/8/2015Cantor FitzgeraldReiterated RatingBuy$21.00View Rating Details
9/30/2014Brean CapitalDowngradeBuy -> HoldView Rating Details
9/29/2014Citigroup Inc.Reiterated RatingNeutral$8.00 -> $10.00View Rating Details
9/25/2014Chardan CapitalReiterated RatingPositiveView Rating Details
(Data available from 9/24/2014 forward)

Earnings

Earnings History for Endocyte (NASDAQ:ECYT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2016        
8/4/2016Q2($0.26)($0.25)ViewN/AView Earnings Details
5/4/2016Q116($0.25)($0.24)ViewListenView Earnings Details
3/2/2016Q4($0.27)($0.23)$0.01 millionViewListenView Earnings Details
11/3/2015Q315($0.27)($0.24)$0.03 millionViewN/AView Earnings Details
8/4/2015Q215($0.30)($0.25)ViewN/AView Earnings Details
5/7/2015Q115($0.24)($0.26)ViewN/AView Earnings Details
3/2/2015Q414($0.25)($0.19)$2.55 million$12.00 millionViewN/AView Earnings Details
11/5/2014Q314($0.21)($0.14)$5.10 million$3.90 millionViewN/AView Earnings Details
7/29/2014Q214$0.10$0.52$26.62 million$49.17 millionViewN/AView Earnings Details
5/2/2014Q114($0.14)($0.09)$15.07 million$17.30 millionViewN/AView Earnings Details
2/24/2014Q413($0.14)($0.08)$15.90 million$17.30 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.06)($0.11)$14.24 million$14.50 millionViewN/AView Earnings Details
4/15/2013Q413($0.10)$8.50 million$13.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Endocyte (NASDAQ:ECYT)
Current Year EPS Consensus Estimate: $-1.11 EPS
Next Year EPS Consensus Estimate: $-1.27 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.29)($0.27)($0.28)
Q2 20162($0.29)($0.27)($0.28)
Q3 20162($0.30)($0.29)($0.30)
Q4 20161($0.29)($0.29)($0.29)
Q1 20171($0.32)($0.32)($0.32)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.33)($0.33)($0.33)
Q4 20171($0.34)($0.34)($0.34)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Endocyte (NASDAQ:ECYT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Endocyte (NASDAQ:ECYT)
Insider Ownership Percentage: 16.62%
Institutional Ownership Percentage: 36.48%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2016Philip S LowInsiderBuy11,375$3.52$40,040.00View SEC Filing  
1/19/2016Fred A. MiddletonDirectorBuy10,000$2.79$27,900.00View SEC Filing  
1/15/2016Fred A. MiddletonDirectorBuy20,000$2.80$56,000.00View SEC Filing  
4/9/2014Allen RitterVPSell1,000$21.16$21,160.00View SEC Filing  
3/21/2014Allen RitterVPSell8,000$33.11$264,880.00View SEC Filing  
2/14/2014Philip LowInsiderSell6,000$15.00$90,000.00View SEC Filing  
12/2/2013P Ron EllisCEOSell3,000$12.00$36,000.00View SEC Filing  
9/16/2013Allen RitterVPSell2,000$17.06$34,120.00View SEC Filing  
9/12/2013David MeekInsiderSell10,000$15.50$155,000.00View SEC Filing  
9/3/2013P Ron EllisCEOSell3,000$14.54$43,620.00View SEC Filing  
8/30/2013Allen RitterVPSell6,000$14.36$86,160.00View SEC Filing  
8/6/2013Chandra LovejoyVPSell7,000$17.29$121,030.00View SEC Filing  
8/1/2013P Ron EllisCEOSell3,000$18.12$54,360.00View SEC Filing  
7/15/2013P Ron EllisCEOSell3,000$17.01$51,030.00View SEC Filing  
5/28/2013Ann HanhamDirectorSell9,900$14.10$139,590.00View SEC Filing  
5/22/2013Ann HanhamDirectorSell40,000$14.38$575,200.00View SEC Filing  
5/17/2013Ann HanhamDirectorSell37,200$14.41$536,052.00View SEC Filing  
5/17/2013Binh NguyenVPSell17,300$14.42$249,466.00View SEC Filing  
5/15/2013Ann HanhamDirectorSell40,200$14.69$590,538.00View SEC Filing  
5/14/2013Christopher P LeamonVPSell5,000$14.70$73,500.00View SEC Filing  
2/25/2013Chandra D LovejoyVPSell2,102$9.70$20,389.40View SEC Filing  
12/26/2012Chandra D LovejoyVPSell2,209$9.05$19,991.45View SEC Filing  
11/26/2012Chandra D LovejoyVPSell2,209$8.72$19,262.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Endocyte (NASDAQ:ECYT)
DateHeadline
News IconWhat are Research Firms Saying About Endocyte, Inc. (NASDAQ:ECYT)? - Frisco Fastball (NASDAQ:ECYT)
friscofastball.com - September 24 at 9:25 AM
investornewswire.com logoShares Of Endocyte, Inc. (NASDAQ:ECYT) Expected To Hit $8 - Investor Newswire (NASDAQ:ECYT)
www.investornewswire.com - September 22 at 10:21 AM
News IconEndocyte, Inc. (ECYT) Given Outperform Rating at Wedbush - DailyQuint (NASDAQ:ECYT)
dailyquint.com - September 21 at 9:03 AM
News IconPenny Stock Investors Take an Interest in Endocyte, Inc. (NASDAQ:ECYT) - Duncan Research (NASDAQ:ECYT)
www.duncanindependent.com - September 21 at 9:03 AM
finance.yahoo.com logoEndocyte to Present at the Ladenburg Thalmann 2016 Healthcare Conference (NASDAQ:ECYT)
finance.yahoo.com - September 21 at 9:02 AM
News IconUnder the Microscope: Getting a Closer Look at Shares of Endocyte, Inc. (NASDAQ:ECYT) - Duncan Research (NASDAQ:ECYT)
www.duncanindependent.com - September 19 at 3:37 PM
News IconCheck on Share Volatility: Endocyte, Inc. (NASDAQ:ECYT) - DailyQuint (NASDAQ:ECYT)
dailyquint.com - September 17 at 4:38 PM
News IconStock Update, a Closer Look at Endocyte, Inc. (NASDAQ:ECYT) - Duncan Research (NASDAQ:ECYT)
www.duncanindependent.com - September 15 at 5:06 PM
News IconKeen Investors Narrowing Their Focus on Endocyte, Inc. (NASDAQ:ECYT) - Duncan Research (NASDAQ:ECYT)
www.duncanindependent.com - September 14 at 9:57 PM
News IconStock Perspective: Endocyte, Inc. (NASDAQ:ECYT) Earnings in View - Frisco Fastball (NASDAQ:ECYT)
friscofastball.com - September 13 at 9:38 AM
News IconGetting a Closer Look at Shares of Endocyte, Inc. (NASDAQ:ECYT) - Duncan Research (NASDAQ:ECYT)
www.duncanindependent.com - September 12 at 4:35 PM
News IconGetting a Closer Look at Shares of Endocyte, Inc. (NASDAQ:ECYT) - Duncan Research (NASDAQ:ECYT)
www.duncanindependent.com - September 12 at 4:35 PM
News IconPlacing Endocyte, Inc. (NASDAQ:ECYT) Shares Under the Microscope - Post News (NASDAQ:ECYT)
www.kentuckypostnews.com - September 9 at 4:38 PM
News IconStock Struggling for the Quarter: Endocyte, Inc. (NASDAQ:ECYT) - Post News (NASDAQ:ECYT)
www.kentuckypostnews.com - September 4 at 4:27 PM
capitalcube.com logoETF’s with exposure to Endocyte, Inc. : September 2, 2016 (NASDAQ:ECYT)
www.capitalcube.com - September 2 at 4:41 PM
News IconStock in Review: Taking a Closer Look at Endocyte, Inc. (NASDAQ:ECYT) Shares - Post News (NASDAQ:ECYT)
www.kentuckypostnews.com - September 2 at 9:39 AM
investornewswire.com logoEndocyte, Inc. (NASDAQ:ECYT) Gets 0 Recommendations To Sell - Investor Newswire (NASDAQ:ECYT)
www.investornewswire.com - August 24 at 4:42 PM
investornewswire.com logoWill Endocyte, Inc. (NASDAQ:ECYT) Hit $8 Price Target? - Investor Newswire (NASDAQ:ECYT)
www.investornewswire.com - August 17 at 4:57 PM
finance.yahoo.com logoENDOCYTE INC Financials (NASDAQ:ECYT)
finance.yahoo.com - August 16 at 4:49 PM
finance.yahoo.com logoEndocyte Announces Presentations at the 252nd American Chemical Society National Meeting & Exposition (NASDAQ:ECYT)
finance.yahoo.com - August 15 at 4:53 PM
capitalcube.com logoETF’s with exposure to Endocyte, Inc. : August 15, 2016 (NASDAQ:ECYT)
www.capitalcube.com - August 15 at 11:58 AM
capitalcube.com logoEndocyte, Inc. :ECYT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:ECYT)
www.capitalcube.com - August 12 at 4:46 PM
globenewswire.com logoEndocyte to Present at the 2016 Wedbush PacGrow Healthcare Conference - GlobeNewswire (press release) (NASDAQ:ECYT)
globenewswire.com - August 10 at 4:57 PM
nasdaq.com logoEndocyte (ECYT) Q2 Loss Wider than Expected (Revised) - Nasdaq (NASDAQ:ECYT)
www.nasdaq.com - August 9 at 8:59 PM
finance.yahoo.com logoEndocyte to Present at the 2016 Wedbush PacGrow Healthcare Conference (NASDAQ:ECYT)
finance.yahoo.com - August 9 at 8:59 PM
finance.yahoo.com logoEndocyte (ECYT) Q2 Loss Wider than Expected (Revised) (NASDAQ:ECYT)
finance.yahoo.com - August 9 at 7:46 AM
finance.yahoo.com logoEndocyte (ECYT) Reports Narrower-than-Expected Loss in Q2 (NASDAQ:ECYT)
finance.yahoo.com - August 5 at 4:48 PM
finance.yahoo.com logoEdited Transcript of ECYT earnings conference call or presentation 4-Aug-16 8:30pm GMT (NASDAQ:ECYT)
finance.yahoo.com - August 5 at 4:48 PM
biz.yahoo.com logoENDOCYTE INC Files SEC form 10-Q, Quarterly Report (NASDAQ:ECYT)
biz.yahoo.com - August 5 at 4:48 PM
nasdaq.com logoEarnings Reaction History: Endocyte, Inc., 80.0% Follow-Through Indicator, 14.6% Sensitive - Nasdaq (NASDAQ:ECYT)
www.nasdaq.com - August 5 at 8:17 AM
twst.com logoEndocyte Inc.: Endocyte Reports Second Quarter 2016 Financial Results (NASDAQ:ECYT)
www.twst.com - August 4 at 10:29 PM
sg.finance.yahoo.com logoEndocyte reports 2Q loss (NASDAQ:ECYT)
sg.finance.yahoo.com - August 4 at 10:29 PM
publicnow.com logoEndocyte Reports Second Quarter 2016 Financial Results (NASDAQ:ECYT)
www.publicnow.com - August 4 at 4:58 PM
equities.com logoEndocyte Inc. (ECYT) is Trading Lower on Unusual Volume for August 02 - Equities.com (NASDAQ:ECYT)
www.equities.com - August 4 at 7:53 AM
publicnow.com logoEndocyte Announces Second Quarter 2016 Earnings Conference Call (NASDAQ:ECYT)
www.publicnow.com - July 28 at 4:18 PM
finance.yahoo.com logoWhta's in Store for Endocyte (ECYT) this Earnings Season? (NASDAQ:ECYT)
finance.yahoo.com - July 28 at 10:59 AM
investornewswire.com logoCan Shares Of Endocyte, Inc. (NASDAQ:ECYT) Hit $8? - Investor Newswire (NASDAQ:ECYT)
www.investornewswire.com - July 27 at 4:53 PM
News IconEarnings Focus and Crowd Sourced Sentiment Review for Endocyte, Inc. (NASDAQ:ECYT) - TGP (NASDAQ:ECYT)
telanaganapress.com - July 22 at 8:16 AM
capitalcube.com logoETF’s with exposure to Endocyte, Inc. : July 21, 2016 (NASDAQ:ECYT)
www.capitalcube.com - July 21 at 1:57 PM
investornewswire.com logoIs $8 Price Target Attainable For Endocyte, Inc. (NASDAQ:ECYT)? - Investor Newswire (NASDAQ:ECYT)
www.investornewswire.com - July 21 at 8:15 AM
News IconEndocyte Incorporated (NASDAQ:ECYT) Sellers Covered 7.44% of Their Shorts - Consumer Eagle (NASDAQ:ECYT)
www.consumereagle.com - July 20 at 5:58 PM
News IconWere Analysts Bearish Endocyte, Inc. (NASDAQ:ECYT) This Week? - Consumer Eagle (NASDAQ:ECYT)
www.consumereagle.com - July 20 at 7:55 AM
News IconEquity Roundup: Stock Performance Focus on Endocyte, Inc. (NASDAQ:ECYT) - Press Telegraph (NASDAQ:ECYT)
presstelegraph.com - July 19 at 10:52 AM
News IconShares Moving Down on the Week: Endocyte, Inc. (NASDAQ:ECYT) - Engelwood Daily (NASDAQ:ECYT)
www.engelwooddaily.com - July 18 at 4:53 PM
News IconEndocyte Incorporated (NASDAQ:ECYT) Shorted Shares Decreased By 8.99% - Press Telegraph (NASDAQ:ECYT)
presstelegraph.com - July 15 at 11:47 AM
News IconInsiders Increasing Positions in: Endocyte, Inc. (NASDAQ:ECYT) - Press Telegraph (NASDAQ:ECYT)
presstelegraph.com - July 15 at 11:47 AM
News IconCrowd Rating and Earnings Recap for Endocyte, Inc. (NASDAQ:ECYT) - Telanagana Press (NASDAQ:ECYT)
telanaganapress.com - July 15 at 11:47 AM
News IconEndocyte, Inc. (NASDAQ:ECYT) Wall Street Analyst Recommendation Outlook - Telanagana Press (NASDAQ:ECYT)
telanaganapress.com - July 14 at 5:40 AM
investornewswire.com logoStrong Sell Calls For Endocyte, Inc. (NASDAQ:ECYT) At 0 - Investor Newswire (NASDAQ:ECYT)
www.investornewswire.com - July 14 at 5:40 AM
News IconEarnings Check and Company Target Review for Endocyte, Inc. (NASDAQ:ECYT) - Press Telegraph (NASDAQ:ECYT)
presstelegraph.com - July 13 at 4:57 PM

Social

Endocyte (NASDAQ:ECYT) Chart for Saturday, September, 24, 2016


Last Updated on 9/24/2016 by MarketBeat.com Staff